Galectin Therapeutics reported $25.6M in Cash and Equivalent for its fiscal quarter ending in June of 2024.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Galectin Therapeutics USD 25.6M 2.04M Jun/2024
Gilead Sciences USD 7.63B 64M Mar/2026
Immunic USD 186.63M 171.15M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Merck USD 5.33B 9.24B Mar/2026